Shao Wenxia
Department of Clinical Laboratory, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Front Med (Lausanne). 2022 Jun 29;9:949554. doi: 10.3389/fmed.2022.949554. eCollection 2022.
SARS-CoV-2 is a serious infectious respiratory virus that can cause lung, heart, kidney, and liver damage and even cause death. Early diagnosis of SARS-CoV-2 infection is vital for epidemic prevention and control. At present, the gold standard of COVID-19 diagnosis is nucleic acid detection of SARS-CoV-2. However, the nucleic acid detection of SARS-CoV-2 requires high site requirements and technology requirements, and the detection is time-consuming and cannot fully meet clinical needs. Although SARS-CoV-2 antigen test results cannot be directly used to diagnose COVID-19, positive results can be used for the early triage and rapid management of suspected populations. However, due to the limitations of the methodology itself, the SARS-CoV-2 antigen test is prone to produce false-positive and false-negative results in the process of detection. It is urgent to develop a batch of SARS-CoV-2 antigen reagents based on new detection technology and detection principles to overcome the defects of existing technologies.
严重急性呼吸综合征冠状病毒2(SARS-CoV-2)是一种严重的传染性呼吸道病毒,可导致肺部、心脏、肾脏和肝脏损伤,甚至导致死亡。SARS-CoV-2感染的早期诊断对于疫情防控至关重要。目前,2019冠状病毒病(COVID-19)诊断的金标准是SARS-CoV-2核酸检测。然而,SARS-CoV-2核酸检测对场地要求和技术要求较高,检测耗时且不能完全满足临床需求。虽然SARS-CoV-2抗原检测结果不能直接用于诊断COVID-19,但阳性结果可用于疑似人群的早期分流和快速管理。然而,由于方法本身的局限性,SARS-CoV-2抗原检测在检测过程中容易产生假阳性和假阴性结果。迫切需要开发一批基于新检测技术和检测原理的SARS-CoV-2抗原试剂,以克服现有技术的缺陷。